Benjamin R. Yerxa, President and Director of Opus Genetics, Inc., filed a Form 4 on October 27, 2026, disclosing two automatic sales of common stock on October 23, 2026, executed to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units.

Key Highlights

  • First transaction: 7,669 shares of common stock were sold at a weighted average price of $3.5514, with individual transactions ranging from $3.5500 to $3.5522 per share.
  • Second transaction: 25,520 shares were sold at a weighted average price of $3.5317, with individual transactions ranging from $3.53 to $3.545 per share.
  • Total shares sold: 33,189 shares disposed of across both transactions on October 23, 2026.
  • Remaining ownership: Following both transactions, Yerxa directly held 670,917 shares of common stock.
  • Non-discretionary sales: According to the filing, the shares "were sold automatically on behalf of the Reporting Person, as required by the Issuer to satisfy tax withholding obligations" and the transactions "do not represent a discretionary trade by the Reporting Person."
  • Reporting person roles: Yerxa is identified in the filing as both a Director and President of Opus Genetics, Inc.

Automatic RSU Tax-Withholding Sales by Opus Genetics President Yerxa on October 23, 2026

Benjamin R. Yerxa, serving as President and Director of Opus Genetics, Inc. (NASDAQ:IRD), reported two disposals of common stock on October 23, 2026, both coded as sales (transaction code "S") in Table I of the filing. The filing states that both sales were carried out automatically by the issuer to cover tax withholding obligations connected to the vesting and settlement of restricted stock units, and that neither transaction was a discretionary trade by Yerxa.

The first sale involved 7,669 shares at a weighted average price of $3.5514. According to the filing, these shares were sold in multiple transactions at prices ranging from $3.5500 to $3.5522, inclusive. After this transaction, Yerxa's directly held beneficial ownership stood at 696,437 shares. The second sale on the same date covered 25,520 shares at a weighted average price of $3.5317, with individual sale prices ranging from $3.53 to $3.545, inclusive, reducing Yerxa's directly held position to 670,917 shares.

The filing notes that Yerxa undertakes to provide full information on the number of shares sold at each separate price within the stated ranges, upon request by the issuer, any securityholder, or the SEC staff. No derivative securities transactions were reported in Table II. The Form 4 was signed by Amy Rabourn, by Power of Attorney, and filed on October 27, 2026.

What Was Disclosed

Opus Genetics President and Director Benjamin R. Yerxa disclosed two automatic, non-discretionary sales totaling 33,189 common shares on October 23, 2026, to satisfy RSU tax withholding obligations, leaving him with a direct beneficial ownership of 670,917 shares.